Furthermore, high MIF expression levels are strongly correlated with poor clinical prognosis in advanced melanoma and was involved in poor responses to anti-CTLA-4 therapy (Ekmekcioglu et al., 2016; Yaddanapudi et al., 2016). This evidence concerns the gene MIF and melanoma.